When was Senti Bio founded?

Senti Bio was founded in 2016 and raised its 1st funding round 2 years after it was founded.

Where is Senti Bio located?

Senti Bio is headquartered in San Francisco, United States. It is registered at 2 Corporate Drive, First Floor South San Francisco, CA 94080.

Who is the current CEO of Senti Bio?

Tim Lu of Senti Bio. They have also founded 1 company.

How many employees does Senti Bio have?

As of Jun 30, 2026, the latest employee count at Senti Bio is 65.

Is Senti Bio a funded company?

Senti Bio is a funded company, having raised a total of $158M across 8 funding rounds to date. The company's 1st funding round was a $***** Grant (prize money) round, raised on Jan 01, 2018.

When was the latest funding round of Senti Bio?

Senti Bio's latest funding was a $***** Post IPO round on May 02, 2026, with participation from 1 investor.

What is the annual revenue of Senti Bio?

Annual revenue of Senti Bio is less than $1M as on Dec 31, 2025

Where does Senti Bio rank among its competitors?

Senti Bio ranks 3rd amongst 3403 active competitors, of which 1164 are funded. It stands 7th in terms of total funding among its competitors. The most recent competitor to raise funding was Immuneel, which secured $10.5M in Jun, 2026.

Who are the top competitors of Senti Bio?

Senti Bio's top competitors include Jazz Pharmaceuticals, Sana Biotechnology and Ideaya Biosciences. Among them, Immuneel secured the most recent funding round in June, 2026.

Senti Bio - 2026 Company Profile, Team, Funding, Competitors & Financials

Company Details

Developer of cell and gene therapies for patients living with incurable diseases. The company has developed its proprietary synthetic biology platform to produce cell and gene therapies for cancer treatment. The company's pipeline is comprised of cell therapies engineered with Gene Circuits to target difficult to treat liquid and solid tumors. It offers CAR-NK-based therapies for multiple cancer and tumors.

Website: sentibio.com
Social
Email ID: *****@sentibio.com
Registered Address: 2 Corporate Drive, First Floor South San Francisco, CA 94080

Key Metrics

Founded Year

2016

Location

San Francisco, United States

Stage

Public

Total Funding

$158M in 8 rounds

Latest Funding Round

Post IPO, May 02, 2026, $*****

Investors

Celadon Partners & 31 more

Ranked

3^rd among 3403 active competitors

Annual Revenue

$0 - $1M as on Dec 31, 2025

Employee Count

65 as on Jun 30, 2026

Similar Companies

Bluebird Bio & 284 more

Exit Details

Public

View Senti Bio's full profile

Senti Bio is associated with 1 legal entity given below:

Legal Entity Name	Date of Incorporation	Revenue	Latest Employee Count	Documents
Senti Biosciences, Inc. CIN: 1854270 , United States, Active	Feb 28, 2021	$0 - $1M (As on Dec 31, 2025)	-	-

Senti Bio got listed on Sep 17, 2021.

Click here to take a look at Senti Bio's IPO in detail

Senti Bio has raised a total funding of $158M over 8 rounds. Its first funding round was on Jan 01, 2018. Its latest funding round was a Post IPO round on May 02, 2026 for $*****. 1 investor participated in its latest round. Senti Bio has 32 institutional investors.

Here is the list of recent funding rounds of Senti Bio:

Filter this list

Date of Funding	Funding Amount	Round Name	Post-Money Valuation	Revenue Multiple	Lead Investors	Other Investors
May 02, 2026	7002132	Post IPO	6811526	7520172	9440556	8916015
Dec 02, 2024	4630809	Post IPO	4376516	1607988	4536051	New Enterprise Associates & 3 more
Dec 02, 2024	1705663	Post IPO	9958594	1864250	Celadon Partners	New Enterprise Associates & 3 more

Access funding benchmarks and valuations. Sign up today!

View details of Senti Bio's funding rounds and investors

The founders of Senti Bio are Tim Lu, Philip Lee, Wilson Wong and Jim Collins. Tim Lu is the CEO of Senti Bio.

Here are the details of Senti Bio's key team members:

Tim Lu: Co-Founder & CEO of Senti Bio and founder of 1 other company.
Contact Info: 2 email addresses
Philip Lee: CTO of Senti Bio.
Contact Info: 1 email address
Wilson Wong: Co-Founder of Senti Bio.
Contact Info: 1 email address
Jim Collins: Co-Founder of Senti Bio.
Contact Info: 1 email address

View details of Senti Bio's Founder profiles and Board Members

Senti Bio's employee count trend

Senti Bio has 65 employees as of Jun 26. Here is Senti Bio's employee count trend over the years:

Uncover Senti Bio's growth story! Sign up today!

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of Senti Bio include Jazz Pharmaceuticals, Sana Biotechnology and Ideaya Biosciences. Here is the list of Top 10 competitors of Senti Bio, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	Jazz Pharmaceuticals 2003, Dublin (Ireland), Public	Developer of novel biopharmaceutical medicines for unmet medical needs	$265M	Versant Ventures, Prospect Venture Partners ... & 14 others	82/100
2nd	Sana Biotechnology 2018, Seattle (United States), Public	Developer of engineered cell therapies for treating various human diseases	$821M	Baillie Gifford, Google Ventures & 17 others	75/100
3rd	Senti Bio 2016, San Francisco (United States), Public	Developer of cell and gene therapies for patients living with incurable diseases	$158M	Allen & Company, Nantahala Capital Management ... & 30 others	72/100
4th	Ideaya Biosciences 2015, San Francisco (United States), Public	Developer of oncology-focused precision medicine using molecular diagnostics	$157M	BVF Partners, Boxer Capital & 15 others	72/100
5th	Sutro Biopharma 2003, United States, Public	Developer of antibody-based therapeutics for cancer therapy	$175M	Skyline Ventures, Alta Partners & 17 others	72/100
6th	Syndax 2005, Waltham (United States), Public	Developer of targeted therapies for the treatment of cancer	$198M	Fidelity Investments, Domain Associates & 19 others	72/100
7th	Karyopharm 2008, Newton (United States), Public	Biopharmaceutical company focused on developing and commercializing innovative cancer therapies	$98.4M	Foresite Capital, Avidity Partners & 16 others	71/100
8th	Moderna 2010, Cambridge (United States), Public	Developer of mRNA-based therapeutics for a wide range of diseases	$2.78B	Merck, AstraZeneca & 32 others	71/100
9th	C4 Therapeutics 2016, Cambridge (United States), Public	Developer of small molecule drugs for treating cancer	$223M	Cobro Ventures, Perceptive Advisors & 27 others	71/100
10th	Immuneel 2018, Bengaluru (India), Series B	Developer of T-cell therapies for the treatment of cancer	$49.8M	True North, F-Prime Capital & 23 others	71/100